BPC 157 for athletes and injury treatment: Science, safety, and legal concerns An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 + TB 500 blend 10mg (RUO) Tide Labs Tide Labs